Resources

In this blog, Justin Wilson, Withers & Rogers LLP, shares his expert perspective on what the recent patent rulings from the Unified Patent Court (UPC) and the Court of Justice of the European Union (CJEU) mean in practice for biotech and pharma companies.

Find out about how opposition parties are positioning themselves in an increasingly fragmented political landscape, and what it might mean for our sector now and in the long term.

Coulter Partners successfully completed a search assignment Proveca and is pleased to announce the placement of Gregory Reinaud as Chief Operating Officer (COO).

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch. 

A new science specialist sixth form is set to open next year, based at Sandwich Science and Innovation Campus, Discovery Park. The new sixth form is named Carbon 6 Academy of Science, ideal for ambitious students aged 16-18 with a passion for science and maths.

Caroline founded Amici in 2005, building a company that scientists trust to power intelligent LabOps, the discipline behind efficient, compliant, and cost-effective labs. Today, Amici partners with biotech's and major pharma companies across the UK, Europe, and the US.

Precision BioSearch is delighted to have supported Maxion Therapeutics, a pioneering biotechnology company developing antibody-based drugs for ion channel and GPCR-driven diseases, with the appointment of Joel Edwards as Chief Business Officer.

Pharma multinational bets on candidates invented by GLP-1 pioneer Prof Steve Bloom to propel it into the race for next-generation obesity treatments.

VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now available on BioRxiv.

How are pharmaceutical companies, policymakers and investors seeking growth amid fast-changing international politics, trade deals, a looming patent cliff, and technological innovation? Our maiden Life sciences and healthcare insights report offers a global perspective on disruptive forces from artificial intelligence to regulatory shifts.

In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in neurodegeneration and neuroinflammation applications.

BIA and Japan Bioindustry Association signed an MOU, agreeing to work together to connect the two countries’ life sciences and biotech ecosystems to accelerate medical innovation and the commercialisation of engineering biology.

Complement Therapeutics receives FDA IND clearance to advance its lead gene therapy CTx001 into Opti-GAIN, a Phase I/II clinical trial in Geographic Atrophy secondary to AMD

MDC will accelerate innovative life science business growth through upskilling and capability development

Maddy and Emma from BIA's policy and public affairs team report and reflect on the mood in Liverpool, and pull out the key insights for our sector.

Every two years, Cytiva surveys 1250 biopharma executives across 22 countries and asks them to rate, on a scale of 0 to 10, the biopharma ecosystem across six pillars: supply chain resilience, talent pool, R&D ecosystem, manufacturing agility, government policy and regulation.